<DOC>
	<DOCNO>NCT02015871</DOCNO>
	<brief_summary>This trial open-label , multi-centre , single arm extension 000006 trial Chinese patient prostate cancer . Eligible patient receive monthly ( 28-day interval ) maintenance dose 80 mg ( 20 mg/mL ) degarelix administer subcutaneous ( s.c. ) injection period 2 year first visit extension trial . Patients , receive goserelin treatment main trial , get degarelix start dose ( 240 mg ; 40 mg/mL ) first visit continue degarelix treatment . The purpose 2-year extension trial collect long-term safety tolerability data one-month dosing regimen .</brief_summary>
	<brief_title>An Extension Long-term Safety Tolerability Trial Degarelix Chinese Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has give write informed consent trialrelated activity perform . A trialrelated activity define procedure would perform normal management patient Has complete 000006 trial Has withdrawn/discontinued 000006 trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>